Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 2Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 17Docetaxel 13Specimen Handling 12Radiotherapy 11Surveys and Questionnaires 10Cyclophosphamide 10Blood Specimen Collection 9Radiosurgery 8Paclitaxel 8Gemcitabine 8Drug Therapy 8sargramostim 7Trastuzumab 7Nivolumab 7Carboplatin 7Injections 6Early Intervention, Educational 6Taxes 5Psychiatric Rehabilitation 5Methods 5Interviews as Topic 5Educational Status 5spartalizumab 4motexafin gadolinium 4aldesleukin 4X-Rays 4Therapeutics 4Standard of Care 4Spinal Puncture 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Canagliflozin × Breast × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡